[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"oral-anti-tumor-drugs\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:oral-anti-tumor-drugs":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100644903","educational-intervention-on-oral-anticancer-agents-for-community-pharmacists-pilot-rct-100644903",false,"NCT07677176","Educational Intervention on Oral Anticancer Agents for Community Pharmacists: Pilot RCT","Feasibility and Acceptability of an Educational Intervention on Oral Anticancer Agents for Community Pharmacists: a Pilot Randomized Controlled Trial","Inclusion Criteria:\n\n* Currently a registered pharmacist working in community pharmacy in Malaysia\n* Provided written informed consent\n* Ability to read and understand English\n* Basic digital literacy and ability to use computer\u002Ftablet devices\n* Willingness to participate in all study procedures including surveys and potential interviews\n\nExclusion Criteria:\n\n• Previous participation in educational intervention stakeholder evaluation",true,"ALL","18 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"NA","The overall aim of this study is to develop and test the feasibility and acceptability of an educational intervention for community pharmacists to help them support patients receiving OAAs in the community setting. This pilot randomized controlled trial aims to evaluate the feasibility, acceptability, and preliminary effect of an educational intervention on the knowledge and readiness in managing OAAs among community pharmacists in Malaysia.\n\nPRIMARY OBJECTIVE • To evaluate the feasibility and acceptability of the educational intervention on OAAs among community pharmacists.\n\nSECONDARY OBJECTIVE\n\n• To obtain preliminary data on the effectiveness of the educational intervention to improve community pharmacists' knowledge and confidence in managing OAAs.\n\nParticipants will be randomly assigned to either the intervention group or control group in a 1:1 ratio using block randomization. After enrolling, participants will be asked to complete a baseline survey assessing their knowledge and confidence about managing OAAs. Immediately after completing the intervention, participants in the intervention group will repeat the same questionnaire to assess changes in their knowledge and confidence.\n\nResults of this pilot study will inform the design of a larger study to definitively test whether this intervention improves community pharmacists' knowledge and readiness. This research may help better prepare community pharmacists to provide high-quality care to patients receiving OAAs.",[27,28,29],"Oral Anti-Tumor Drugs","Oral Antineoplastic Agents","Oral Anticancer Drugs",[31,32,33],"Community pharmacists","Oral anticancer agents","Educational intervention","NOT_YET_RECRUITING","2026-06-24",{"date":37,"type":38},"2026-06-30","ACTUAL",{"date":40,"type":21},"2026-08",{"date":42,"type":21},"2026-11",{"name":44,"class":45},"Monash University Malaysia","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":61,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":46},"100612840","evaluation-of-tolerance-and-quality-of-life-in-patients-with-neuroendocrine-tumors-treated-with-oral-anti-tumor-drugs-within-a-therapeutic-education-program-100612840","NCT07258810","Evaluation of Tolerance and Quality of Life in Patients With Neuroendocrine Tumors Treated With Oral Anti-Tumor Drugs Within a Therapeutic Education Program","ETP-NET","Inclusion Criteria:\n\n* Adult patient (\\>18 years) at the time of the study\n* Patient diagnosed with a neuroendocrine tumor (NET) with an indication for treatment with oral anti-tumor agents (everolimus, sunitinib, cabozantinib, temozolomide +\u002F- capecitabine, others including lenvatinib)\n* Collection of the patient's non-opposition to participate in the study\n\nExclusion Criteria:\n\n* Minors\n* Pregnant, parturient, or breastfeeding women\n* Persons deprived of liberty by judicial or administrative decision\n* Adults under legal protection measures (guardianship, conservatorship)\n* Refusal to participate in the study",{"count":55,"type":21},100,"OBSERVATIONAL","In recent years, the arrival of targeted oral therapies has greatly changed cancer treatment. These therapies help patients stay independent by reducing the number of hospital visits, since the treatment is given at home. However, this way of giving treatment brings specific challenges, especially in managing side effects and making sure patients follow their treatment properly.\n\nBecause of this, many patient education programs have been created to help patients learn how to manage their treatment on their own. Although only a few studies have formally looked at how useful these programs are, the available information suggests that they help patients handle side effects better and follow their treatment more closely.\n\nNeuroendocrine tumors are a diverse group of tumors that are becoming more common. More patients with these tumors are now treated with targeted oral therapies such as everolimus, sunitinib, cabozantinib, or chemotherapy with temozolomide and capecitabine.\n\nThese treatments are often given together with a patient education program. However, so far, no study has specifically looked at how helpful these education programs are for this group of patients.",[59,27,60],"Neuroendocrine (NE) Tumors","Therapeutic Education Program",[62,27,60,63,64],"Neuroendocrine tumor","Tolerance","Quality of Life","2025-11-21",{"date":67,"type":38},"2025-12-02",{"date":69,"type":21},"2025-12-01",{"date":71,"type":21},"2027-02-01",{"name":73,"class":45},"Hospices Civils de Lyon"]